Clinical Trial

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Study acronym: ARISTOCRAT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ).
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-04 -> 2026-09 2026-05-06
Trial Details
NCT Number NCT05629702
Lead Sponsor University of Birmingham
Collaborators: University of Leeds, The Brain Tumour Charity, Jazz Pharmaceuticals
Conditions Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
Enrollment 120 participants
Start Date 2023-02-03
Primary Completion 2026-09 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-05